Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (Ccm), Has Met Its Primary Endpoint of Safety and Tolerability
Recursion宣佈REC-994的2期數據，該藥是一種用於症狀性腦海綿狀血管瘤（Ccm）的首個疾病調查性治療方法，已達到其主要終點——安全性和耐受性。
